Lyvgen’s proprietary xLinkMAb functional platform generated agonistic monoclonal antibodies with tumor-localized immunostimulatory activities by balancing multiple functions of candidate antibodies, which has generated several drug candidates, including LVGN7409 (CD40 agonist mAb) and LVGN6051 (4-1BB agonist mAb), presently in clinical development. To increase selectivity for tumors, xLinkAb™ platform creates agonist IgG antibodies that agonize their targets optimally in the presence of FcγRIIb (FCGR2B; CD32B), which is expressed on immune cells enriched in the tumor microenvironment, including B cells, monocytes, and NK cells. A series of Lyvgen's IP protected Fc variants have been designed to achieve selective FcγRIIb binding capacity.
•Nature IgG structure
•Low-affinity and high-avidity binding to FcγRIIB
•High-affinity/specificity binding to TNFRSFs (e.g. CD137, CD40, GITR, OX40)
•FcγRIIB-dependent TNFRSF agonism
•No binding to other activating FcγRs
•No ADCC/ADCP
•IP protected multiple Fc-engineering variants
Lyvgen Biopharma engaged in development of innovative cancer treatment, is open to collaborate or out-license our pipelines or platform technology. Please contact us to explore collaboration opportunities.
沪公网安备 31011502015346号